Veracyte Inc

VCYT
stockHealthcareBiotechnology
$6/day into VCYT since 2015 would be worth $57,971 today — 3.4× the money.
Try your own number →

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Description from Yahoo Finance
Full profile on Yahoo Finance →

If you'd bought from year…

Same habit, different start year. Each row shows what a constant habit's worth of VCYT would be worth today, had you started buying at that point in the asset's history.

Started$6/day$6/day coffee$42/wk$42/week coffee
Year 1 (2013) — listing
$65,133
3.4×
$94,716
3.4×
Year 6 (2018)
$27,812
2.2×
$40,649
2.2×
Year 11 (2023)
$8,706
1.7×
$12,687
1.7×

Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.

Popular scenarios with VCYT

For illustration only — not investment advice. Past performance is not indicative of future results.